FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
August 02, 2016
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates
July 13, 2016
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
July 12, 2016
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
June 02, 2016
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis
May 16, 2016
BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing
August 25, 2016
BRIEF-Galectin Therapeutics Q2 loss per share $0.20
August 09, 2016
13 Biotechnology Stocks to Sell Now
July 18, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here